CPTx — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2020 in Munich, CPTx is a private, pre-clinical biotech developing in vivo CAR-T therapies using a proprietary non-viral platform. Its technology combines long, high-fidelity ssDNA constructs with LNP delivery to enable immune-silent, tunable, and repeatable dosing, aiming to democratize cell therapy. The lead program targets CD19/CD20 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with a broader vision to expand into other cancers and autoimmune diseases. The company operates with an integrated model, controlling platform development, pipeline advancement, and in-house ssDNA manufacturing.

OncologyAutoimmune Diseases

Technology Platform

Proprietary immune-silent single-stranded DNA (ssDNA) vectors delivered via lipid nanoparticles (LNPs) for durable, tunable, and redosable in vivo gene therapy and cell engineering.

Opportunities

The platform could democratize CAR-T therapy by enabling cheaper, faster, and more scalable in vivo administration, potentially capturing a large share of the existing oncology market and expanding into solid tumors and autoimmune diseases.

Internal ssDNA manufacturing capabilities also present a partnership and service revenue opportunity with other biopharma companies.

Risk Factors

Major technical risks include proving the efficacy and safety of in vivo T-cell engineering in humans, a significant leap from animal models.

The company faces intense competition in the in vivo cell therapy space and is dependent on securing ongoing funding as a private, pre-clinical entity.

Competitive Landscape

CPTx competes in the rapidly evolving field of in vivo cell engineering, facing rivals using viral vectors (e.g., lentiviral, AAV), mRNA/LNPs, and other non-viral DNA approaches. Its key differentiator is the focus on immune-silent, long ssDNA for durable, redosable effects, contrasting with permanent viral integration or transient mRNA expression.

More companies in CRISPR / Gene Editing →More companies in Germany →